Target intelligence / Profile preview

Potassium channel tetramerization domain-containing protein 4 (KCTD4)

Target
KCTD4
Molecular classification
Other (BTB/POZ domain-containing protein), Ion channel-associated protein (not an ion channel itself), Ubiquitin ligase complex adaptor (via BTB/POZ domain)
01

Overview

Potassium channel tetramerization domain-containing protein 4 (KCTD4) is a mammalian protein containing a BTB (Broad-Complex, Tramtrack and Bric-a-brac)/POZ (POxvirus and Zinc finger) domain, which facilitates protein–protein interactions and often acts as an adaptor in Cullin 3-containing ubiquitin ligase complexes. Although named for its homology to potassium channel tetramerization domains, KCTD4 does not itself function as a potassium channel, but instead regulates cellular processes via its interaction partners. KCTD4 is strongly implicated in cancer metastasis, especially in esophageal squamous cell carcinoma, where it interacts with CLIC1 to disturb calcium homeostasis and activate NFATc1-dependent gene expression essential for metastatic behavior. KCTD4 is proposed as both a therapeutic target and biomarker for cancer metastasis, with experimental inhibitors under investigation. Broader roles likely include regulation of protein degradation and transcription, in common with other KCTD family members.

Other names
BTB/POZ domain-containing protein KCTD4potassium channel tetramerisation domain containing 4bA321C24.3
02

Mechanism of action

Inhibition of KCTD4–CLIC1 interaction disrupts downstream Ca²⁺ signaling, blocks NFATc1-dependent fibronectin transcription, and suppresses cancer metastasis

03

Biological functions

Protein–protein interaction (via BTB/POZ domain)Regulation of ubiquitination/protein degradation (adaptor for cullin 3 ubiquitin ligase complex)Possible transcriptional regulationRegulation of calcium signaling via interaction with CLIC1Potential roles in cytoskeletal organization
04

Disease associations

Cancer (notably metastasis in esophageal squamous cell carcinoma)Possible roles in other disease processes through protein degradation pathways
05

Safety considerations

Not explicitly reported; as a target for protein–protein interaction modulation, off-target effects due to roles in protein degradation/transcriptional regulation could be a concern based on protein family characteristics
06

Interacting drugs

K279-0738 (lead compound inhibiting KCTD4–CLIC1 interaction, shown to suppress metastasis in cancer models)
07

Biomarkers

High KCTD4 expression is a proposed prognostic biomarker in esophageal cancer (metastatic ESCC)

Beyond the preview

Go deeper on Potassium channel tetramerization domain-containing protein 4 (KCTD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 4 (KCTD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call